BioLine RX Ltd
TASE:BLRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
BioLine RX Ltd
Net Income (Common)
BioLine RX Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
BioLine RX Ltd
TASE:BLRX
|
Net Income (Common)
-$2m
|
CAGR 3-Years
57%
|
CAGR 5-Years
42%
|
CAGR 10-Years
18%
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Net Income (Common)
$20.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
Net Income (Common)
$1.2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Net Income (Common)
-$153.5m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Net Income (Common)
-$11.4m
|
CAGR 3-Years
4%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
Pluri Inc
NASDAQ:PLUR
|
Net Income (Common)
-$26.1m
|
CAGR 3-Years
8%
|
CAGR 5-Years
7%
|
CAGR 10-Years
-2%
|
|
BioLine RX Ltd
Glance View
BioLineRx Ltd. is a clinical stage biopharmaceutical company, which focuses on oncology. The firm is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The firm is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
See Also
What is BioLine RX Ltd's Net Income (Common)?
Net Income (Common)
-2m
USD
Based on the financial report for Dec 31, 2025, BioLine RX Ltd's Net Income (Common) amounts to -2m USD.
What is BioLine RX Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
18%
Over the last year, the Net Income (Common) growth was 78%. The average annual Net Income (Common) growth rates for BioLine RX Ltd have been 57% over the past three years , 42% over the past five years , and 18% over the past ten years .
